343 related articles for article (PubMed ID: 10970683)
21. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of serum levels of cytokines and intercellular adhesion molecule-1 (ICAM-1) in astrocytic tumours.
Nano R; Capelli E; Argentina F; Facoetti A; Gerzeli G
Cell Mol Biol (Noisy-le-grand); 2003 Jun; 49(4):525-8. PubMed ID: 12899444
[TBL] [Abstract][Full Text] [Related]
23. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
Shaarawy M; Darwish NA; Abdel-Aziz O
J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
[TBL] [Abstract][Full Text] [Related]
24. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
[TBL] [Abstract][Full Text] [Related]
25. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.
Wasik MA; Vonderheid EC; Bigler RD; Marti R; Lessin SR; Polansky M; Kadin ME
Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482
[TBL] [Abstract][Full Text] [Related]
26. Serum-soluble IL-2 receptor and IL-6 levels in patients with melanoma.
Boyano MD; García-Vázquez MD; Gardeazabal J; García de Galdeano A; Smith-Zubiaga I; Cañavate ML; Raton JA; Bilbao I; Díaz-Pérez JL
Oncology; 1997; 54(5):400-6. PubMed ID: 9260602
[TBL] [Abstract][Full Text] [Related]
27. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients.
Mouawad R; Soubrane C; Rixe O; Khayat D; Spano JP
Melanoma Res; 2006 Aug; 16(4):335-40. PubMed ID: 16845329
[TBL] [Abstract][Full Text] [Related]
28. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy.
Dejica D
Roum Arch Microbiol Immunol; 2001; 60(3):183-201. PubMed ID: 12165973
[TBL] [Abstract][Full Text] [Related]
29. Soluble interleukin-2 receptors in plasma cell dyscrasias.
Takamatsu T; Yasuda N; Ohno T; Kanoh T; Uchino H; Fujii H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):749-55. PubMed ID: 2618549
[TBL] [Abstract][Full Text] [Related]
30. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
[TBL] [Abstract][Full Text] [Related]
31. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
Bodey B; Psenko V; Lipsey AL; Kaiser HE
Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
[TBL] [Abstract][Full Text] [Related]
32. Serum soluble IL-2 receptor as a reliable and noninvasive marker of disease activity in patients with hairy cell leukemia.
Chrobák L; Podzimek K; Plísková L; Kerekes Z; Zák P; Voglová J; Spacek J; Palicka V
Neoplasma; 1996; 43(5):321-5. PubMed ID: 8996552
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma.
Kalmanti M; Karamolengou K; Dimitriou H; Tosca A; Vlachonikolis I; Peraki M; Georgoulias V; Kalmantis T
Int J Hematol; 1993 Apr; 57(2):147-52. PubMed ID: 8494993
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of serum soluble interleukin 2 receptor-alpha in esophageal squamous cell carcinoma.
Wang LS; Chow KC; Li WY; Liu CC; Wu YC; Huang MH
Clin Cancer Res; 2000 Apr; 6(4):1445-51. PubMed ID: 10778976
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo.
Merkel PA; Dooley MA; Dawson DV; Pisetsky DS; Polisson RP
J Rheumatol; 1996 Nov; 23(11):1856-61. PubMed ID: 8923356
[TBL] [Abstract][Full Text] [Related]
36. The soluble interleukin-2 receptor--a marker for squamous cell carcinoma of the upper aerodigestive tract.
Gottschlich S; Görögh T; Lippert BM; Niemann AM; Folz BJ; Werner JA
Anticancer Res; 1997; 17(4B):2921-2. PubMed ID: 9329564
[TBL] [Abstract][Full Text] [Related]
37. [Clinical course and changes of soluble interleukin-2 receptor and soluble forms of intercellular adhesion molecule-1 (ICAM-1) in serum of multiple sclerosis patients].
Bilińska M; Frydecka I; Podemski R
Neurol Neurochir Pol; 2001; 35(1):47-56. PubMed ID: 11464716
[TBL] [Abstract][Full Text] [Related]
38. Clinical correlations of potential activity markers in systemic sclerosis.
Becvár R; Stork J; Pesáková V; Stánová A; Hulejová H; Rysová L; Zatloukalová A; Zatloukal P; Jáchymová M; Pourová L
Ann N Y Acad Sci; 2005 Jun; 1051():404-12. PubMed ID: 16126982
[TBL] [Abstract][Full Text] [Related]
39. [Levels of soluble intracellular adhesion molecules 1 (sICAM-1) , soluble receptors for interleukin 2 (sIL-2R) and anti-Epstein-Barr viral capsid antigen (anti-VCA IgM) in blood serum during the course of infectious mononucleosis].
Tomasiewicz K; Modrzewska R; Łyczak A; Lis J
Wiad Lek; 2001; 54(3-4):171-8. PubMed ID: 11436683
[TBL] [Abstract][Full Text] [Related]
40. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia.
Moon Y; Kim Y; Kim M; Lim J; Kang CS; Kim WI; Shim SI; Chung NG; Park YH; Min WS; Han K
Ann Clin Lab Sci; 2004; 34(4):410-5. PubMed ID: 15648782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
